These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25203412)

  • 1. Rivaroxaban for treatment of venous thromboembolism in older adults.
    Mitchell AP; Conway SE
    Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
    Pernod G; Elias A; Gouin I; Gaillard C; Nguyen P; Ouvry P; Sié P
    J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
    Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
    Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
    Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
    Romualdi E; Donadini MP; Ageno W
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):841-4. PubMed ID: 21809964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
    Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
    Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.